Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...